| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Original Studies |
Department of Biomedical Sciences, Creighton University School of Medicine (J.Li., J.A.K., T.E.A.), Omaha, Nebraska 68178; and Department of Surgery, Karolinska Institute at the Huddinge Hospital (L.S., J.P., J.La.), Stockholm S14186, Sweden
Address correspondence and requests for reprints to: Thomas E. Adrian, Ph.D., F.R.C.Path., Department of Biomedical Sciences, Creighton University School of Medicine, Omaha, Nebraska 68178. E-mail: tadrian{at}creighton.edu
The diabetes that frequently occurs in pancreatic cancer patients is characterized by profound peripheral insulin resistance. The intracellular mechanism of this insulin resistance was investigated in skeletal muscle biopsies from pancreatic cancer patients with or without diabetes and control subjects.
Insulin receptor (IR) binding, tyrosine kinase activity, IR messenger RNA (mRNA), IR substrate-1 content, GLUT-4, and GLUT-4 mRNA content were all normal in pancreatic cancer patients. In contrast, multiple defects in glycogen synthesis were found in pancreatic cancer patients, especially in those with diabetes. Glycogen synthase I activity, total activity, and mRNA levels were significantly decreased in pancreatic cancer patients compared with controls. The fractional velocity of glycogen synthase was decreased only in the diabetic pancreatic cancer group. Glycogen phosphorylase a and b activities were increased in diabetic pancreatic cancer patients, but glycogen phosphorylase mRNA levels were not significantly different. The insulin resistance associated with pancreatic cancer is associated with a post-IR defect, which impairs skeletal muscle glycogen synthesis and glycogen storage.
This article has been cited by other articles:
![]() |
F. Wang, S. Gupta, and E. A. Holly Diabetes mellitus and pancreatic cancer in a population-based case-control study in the san francisco bay area, california. Cancer Epidemiol. Biomarkers Prev., August 1, 2006; 15(8): 1458 - 1463. [Abstract] [Full Text] [PDF] |
||||
![]() |
D Basso, C Millino, E Greco, C Romualdi, P Fogar, A Valerio, M Bellin, C-F Zambon, F Navaglia, N Dussini, et al. Altered glucose metabolism and proteolysis in pancreatic cancer cell conditioned myoblasts: searching for a gene expression pattern with a microarray analysis of 5000 skeletal muscle genes Gut, August 1, 2004; 53(8): 1159 - 1166. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. Hennig, X.-Z. Ding, W.-G. Tong, M. B. Schneider, J. Standop, H. Friess, M. W. Buchler, P. M. Pour, and T. E. Adrian 5-Lipoxygenase and Leukotriene B4 Receptor Are Expressed in Human Pancreatic Cancers But Not in Pancreatic Ducts in Normal Tissue Am. J. Pathol., August 1, 2002; 161(2): 421 - 428. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Kern, R. Hruban, M. A. Hollingsworth, R. Brand, T. E. Adrian, E. Jaffee, and M. A. Tempero A White Paper: The Product of a Pancreas Cancer Think Tank Cancer Res., June 1, 2001; 61(12): 4923 - 4932. [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Endocrinology | Endocrine Reviews | J. Clin. End. & Metab. |
| Molecular Endocrinology | Recent Prog. Horm. Res. | All Endocrine Journals |